
BDSI
Healthcare · Drug Manufacturers - Specialty & Generic · $577.1M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2022
EPS trend, 90 days to now · -100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 9, 2022 | After the close | 0.02 | 0.62 | +3000.0% |
| Nov 3, 2021 | After the close | 0.06 | 0.07 | +27.3% |
| Aug 4, 2021 | After the close | 0.04 | 0.09 | +104.5% |
| May 6, 2021 | After the close | 0.06 | 0.05 | -16.7% |
| Mar 10, 2021 | After the close | 0.06 | 0.10 | +78.6% |
| Nov 5, 2020 | After the close | 0.05 | 0.09 | +68.9% |
| Aug 5, 2020 | After the close | 0.03 | 0.01 | -70.0% |
| May 7, 2020 | After the close | 0.02 | 0.05 | +192.4% |
| Mar 12, 2020 | After the close | 0.01 | -0.01 | -216.3% |
| Nov 12, 2019 | After the close | -0.02 | 0.00 | +115.7% |
| Aug 8, 2019 | After the close | -0.03 | -0.13 | -282.4% |
| May 6, 2019 | After the close | -0.08 | -0.05 | +34.8% |
| Mar 14, 2019 | After the close | -0.10 | -0.13 |
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug…
| -32.7% |
| Nov 8, 2018 | After the close | -0.14 | -0.29 | -104.2% |
| Aug 9, 2018 | After the close | -0.18 | -0.16 | +12.7% |
| May 10, 2018 | After the close | -0.21 | -0.18 | +14.3% |
| Mar 15, 2018 | After the close | -0.25 | -0.29 | -14.9% |